e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Diffuse pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pirfenidone in idiopathic pulmonary fibrosis - Real life experience from a german tertiary referral centre for interstitial lung diseases
U. Oltmanns, N. Kahn, H. Wenz, C. P. Heussel, M. Puderbach, S. Ehlers-Tenenbaum, A. Warth, F. Herth, P. Schnabel, M. Kreuter (Heidelberg, Germany)
Source:
Annual Congress 2013 –Diffuse pulmonary fibrosis
Session:
Diffuse pulmonary fibrosis
Session type:
Thematic Poster Session
Number:
2335
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
U. Oltmanns, N. Kahn, H. Wenz, C. P. Heussel, M. Puderbach, S. Ehlers-Tenenbaum, A. Warth, F. Herth, P. Schnabel, M. Kreuter (Heidelberg, Germany). Pirfenidone in idiopathic pulmonary fibrosis - Real life experience from a german tertiary referral centre for interstitial lung diseases. Eur Respir J 2013; 42: Suppl. 57, 2335
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Clinical characteristics of patients with Idiopathic pulmonary fibrosis in a tertiary care center of a developing country
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Real life patient experience of pirfenidone in a regional interstitial lung disease clinic
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Proportion of idiopathic pulmonary fibrosis among interstitial lung disease in a tertiary care center and its response to treatment
Source: International Congress 2014 – ILDs 5
Year: 2014
Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
The value of a specialist nurse-lead interstitial lung disease clinic, patients’ views
Source: International Congress 2015 – Kaleidoscope of nursing research
Year: 2015
Review of care in patients dying of pulmonary fibrosis in a district general hospital
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Differing clinical courses of IPF at an acute district general hospital
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Clinical impact of an interstitial lung disease Nurse on patients with idiopathic pulmonary fibrosis
Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias?
Year: 2018
Real life experience with nintedanib in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Assessment of nutritional status in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases
Year: 2016
Changes in the small airways in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
End-of-life care in in-patients dying from pulmonary fibrosis
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
The diagnostic role of cryobiopsy in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Interventional procedures for diagnosis of diffuse lung diseases and peripheral pulmonary lesions
Year: 2013
Variation in mortality from interstitial lung disease by diagnosis
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Non-pulmonary comorbidities in idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Are the gains due to pulmonary rehabilitation in idiopathic pulmonary fibrosis and other interstitial lung diseases the same?
Source: Virtual Congress 2020 – The multiple facets of pulmonary rehabilitation and chronic respiratory care
Year: 2020
The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital
Source: International Congress 2014 – ILDs 4
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept